Libevitug

立贝韦塔单抗

Report date: 2026/05/16 20:00:17

Base Information

Drug NameLibevitug
Drug Alias Name华优诺HH-003
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionLarge envelope protein Pre-S1 inhibitors
TargetsLarge envelope protein Pre-S1
Therapy Area/IndicationsHepatitis D, ChronicHepatitis C, ChronicHepatitis B, Chronic
Global Approved IndicationsHepatitis D, Chronic
Approved Indications in ChinaHepatitis D, Chronic
Original Approved Country/TerritoryMainland China
Original Approved Date2026/01/20
Country/TerritoryPakistanMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesHuahui Health Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHuahui Health Ltd
Inactive CompaniesN/A
Active IndicationsHepatitis D, ChronicHepatitis C, ChronicHepatitis B, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A